AVP and metabolic dysfunction-associated steatotic liver disease: Moreover, copeptin levels were also greater in obese+/NAFLD+ individuals when compared with non-obese subjects without MS and NAFLD (obese−/NAFLD−, mean ± SD copeptin 7.4 ± 5.1 pmol/L; p = 0.01).